FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
Rhea-AI Summary
FibroGen (NASDAQ: FGEN) will present at the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York. Thane Wettig, Chief Executive Officer, will participate in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts" on December 11 at 12:15 PM ET at the Sofitel New York. FibroGen management will be available for one-on-one investor meetings during the conference; investors should contact their Oppenheimer representative to arrange meetings.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FGEN gained 0.50%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FGEN was up 3.7% while close peers showed mixed moves (e.g., VTVT down, ATNM and PDSB up). With only 1 peer in the momentum scanner and mixed directions, today’s action appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Conference appearance | Neutral | +0.5% | Announcement of Oppenheimer rare disease summit presentation and 1x1 investor meetings. |
| Nov 10 | Earnings and update | Neutral | -0.3% | Q3 2025 results, China sale proceeds, cash runway into 2028, clinical updates. |
| Nov 03 | Earnings scheduling | Neutral | -0.1% | Announcement of Q3 2025 earnings date and webcast details for investors. |
| Sep 24 | Clinical trial start | Positive | +3.4% | Initiation of Phase 2 monotherapy trial of FG‑3246 in mCRPC patients. |
| Sep 02 | Asset divestiture | Positive | +3.0% | Completion of FibroGen China sale to AstraZeneca and extension of cash runway. |
Over the past six months, FGEN has often reacted positively to substantive strategic or clinical updates (China sale, FG-3246 Phase 2 initiation), while routine earnings and scheduling announcements have produced only modest moves.
Recent FibroGen news shows a pivot toward strengthening its balance sheet and advancing key programs. On Sep 2, 2025, the company completed the sale of FibroGen China for about $220 million, extending cash runway into 2028. A Sep 24, 2025 update announced initiation of a Phase 2 trial for FG‑3246 in mCRPC. Earnings on Nov 10, 2025 reiterated these themes with Q3 financials and clinical progress. Today’s Dec 2, 2025 conference appearance continues the pattern of investor outreach around these strategic developments.
Market Pulse Summary
This announcement highlights FibroGen’s participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, including a panel focused on near‑term, potentially stock‑moving catalysts and one‑on‑one investor meetings. In context of recent balance sheet strengthening and clinical progress, the event underscores management’s focus on investor outreach. Key items to watch are any new disclosures around upcoming catalysts, clinical timelines, or strategic updates discussed during the conference.
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY.
Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York.
FibroGen’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
FAQ
When and where will FibroGen (FGEN) present at the Oppenheimer Rare Disease Summit?
What time is Thane Wettig speaking for FibroGen (FGEN) on December 11, 2025?
What panel will FibroGen (FGEN) participate in at the Oppenheimer summit?
How can investors schedule one-on-one meetings with FibroGen (FGEN) management at the conference?
Will FibroGen (FGEN) make presentation materials or a webcast available from the December 11, 2025 event?
Who is the FibroGen (FGEN) executive speaking at the Oppenheimer Movers in Rare Disease Summit?
